Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198028 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
A Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01198028: Completed Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT01198028 is a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 58-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01198028, a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Primary Outcome
Overall response rate defined as the percentage of patients who achieve an overall response of complete response or partial response in the total number of evaluable patients, assessed by Response Evaluation Criteria in Solid Tumors 1.1A Bayesian design based on predictive probability will be implemented.
Conditions Studied
Interventions
- DRUG Erlotinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-03-10 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 2 |
What the finished NCT01198028 record still lists
NCT01198028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 58-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (28% lower).
The record links to 2 conditions, with Metastatic Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Erlotinib is the first listed.
NCT01198028 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01198028 about?
NCT01198028 is a clinical study titled "Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma". This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the...
What is the current status of trial NCT01198028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2011-03-10. Estimated completion is 2019-05-01.
What conditions does trial NCT01198028 study?
This clinical trial studies the following conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma.
What interventions are being tested in trial NCT01198028?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01198028?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01198028 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
RECRUITING · Phase 2
-
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
ACTIVE NOT RECRUITING · Phase 2
-
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
RECRUITING · Phase 1
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RECRUITING · Phase 1
-
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI